



Noxopharm Enhances Cash Position via R&D Rebate

Highlights

- Funds received from Australian Government Research and Development Tax Incentive scheme strengthen cash position
- Support for clinical trials, plus Chroma™ and Sofra™ R&D pipelines

Sydney, 10 November 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** has received a \$5.011 million rebate under the Australian Government's Research and Development Tax Incentive scheme for expenditure during FY 2022.

Noxopharm CEO Dr Gisela Mautner said: "This rebate strengthens our cash position at a time of critical research activity to advance our drug development pipeline. Specifically, it will support our ongoing clinical trials for Veyonda®, as well as further our early-stage R&D assets via the Chroma™ and Sofra™ programs.

"The Federal R&D rebate is designed to help companies grow while boosting our nation's economy, and we welcome the Government's support of businesses like ourselves that are harnessing technology in new and sophisticated ways."

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda®, plus two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.